Sun, Jan 21, 2018
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Private Equity Strategies

MicroCap Monitor: DelMar Pharmaceuticals Highlights Continued Activity in Pharma at All Market Caps

Saturday, June 22, 2013

Bailey McCann, Private Equity Strategies

Founded in 2010, DelMar Pharmaceuticals is focused on clinical and commercial stage development of cancer treatment drugs. The company, which recently went public, has been talking to investors highlighting their clinical successes and pipeline projects. Co-Founder and CEO Jeffery Bacha and CFO Scott Praill recently spoke with Private Equity Strategies at the Marcum MicroCap Conference.

“We took the company public through an RTO in January, and it was generally positive,” explains Bacha. “Now we are focused on the trials and telling people our story.”

Unlike other cancer treatment companies, DelMar focuses on patients with on patients with refractory glioblastoma multiforme (GBM), the most common type of aggressive brain cancer. Treatment of this cancer has had mixed success although some drugs are showing promise where standard treatments have failed. Through clinical work in both the US and China, the company has already been awarded an Orphan Drug Designation by US FDA & European EMA for VAL- 083, one of its treatments for glioblastoma. The firm is working on clinical trials this year that look at the possibility of using higher doses of the drug in treatment for glioblastoma multiforme (GBM) and metastatic brain cancer for patients who have failed or are otherwise ineligible for currently approved treatments. This is big news for patients who are faced with a median survival of 4 months from diagnosis without treatment.

The team has been here before, they previously worked at another pharmaceutical firm, NCI on oncology treatments, and brought this knowledge to DelMar. The cancer treatment market as a segment of the broader pharmaceutical market is approximately $78bn. So far, DelMar’s story tracks with other companies in terms of successful IPOs, and positive shareholder value even through turbulent economic conditions.

According to a recent study of the global health care market for private equity by Bain Capital, deal value declined slightly in 2012, even while deal volume remained consistent. This indicator may point to broader interest in microcaps like DelMar. Interest from strategics is also on the rise making it harder for large private equity firms in the US and elsewhere to find deals and deploy capital efficiently.

The report shows that top returns in the health care market will likely come from “healthcare heavy” sectors, which reward risk taking and industry-specific expertise. 70% of the buyout deals done in this space in North America last year were done by small and midsize funds with some expertise in the field. “The implication: In order to unlock top-tier deal returns, funds are going to have to work harder and more creatively in North America to find assets, price them appropriately and create value post-close,” the report says.

Based on a recent analyst report of DelMar, these market factors could be a boon for the company, as they aren’t necessarily focused on acquisition. “We can control our own destiny,” Bacha says. “We have the capital available to us now through our IPO so we can after product revenue and we aren’t dependent on being acquired.”

That said, he notes that even if they sell, the team will probably look to repeat the process again around other products they already have in the pipeline. “The orphan disease market is more profitable than people think,” he says. “It takes skill, but there are a variety of opportunities for investors and companies here.”

 
This article was published in Opalesque's Private Equity Strategies our monthly research update on the global private equity landscape including all sectors and market caps.
Private Equity Strategies
Private Equity Strategies
Private Equity Strategies
Private Equity Strategies


Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. U.S. economy, inflation and alternative investments to dominate 2018 markets, says family office Wilmington Trust[more]

    Komfie Manalo, Opalesque Asia: The emergence of a late-cycle economy in the U.S., the mystery of inflation and growth from a domestic and global perspective, and the potential for alternative investments to prosper against a backdrop of rich valuations, low yields, and higher volatility are the t

  2. Performance - Some hedge funds deliver double-digit gains for 2017, Brevan Howard's hedge fund suffers biggest annual loss in 2017, Crispin Odey's flagship hedge fund plummeted about 20% in 2017, Profits fall 90% at ex-Morgan Stanley banker's hedge fund, Fannie-Freddie overhaul might mint hedge fund riches, losses[more]

    Some hedge funds deliver double-digit gains for 2017 From Reuters/Investing.com: A handful of hedge funds ended 2017 with double digit returns, their investors said, at a time the $3 trillion industry took in fresh money and posted its best returns in years, industry data show. Act

  3. Investing - Hedge funds start 2018 with record $19 billion bet on the euro, Hedge fund Kora Management invests in Satin Creditcare[more]

    Hedge funds start 2018 with record $19 billion bet on the euro From Reuters.com: Hedge funds have kicked off 2018 with their biggest bet ever on the euro rising, a clear vote of confidence in the single currency but, with positioning so stretched, one which could backfire in the near ter

  4. News Briefs - Mobius to retire from Franklin Templeton, Authorities decrypt smart phone of Princeton grad charged with killing Manhattan hedge fund dad, Investigators seize (more) antiques from hedge-fund billionaire Michael Steinhardt's collection[more]

    Mobius to retire from Franklin Templeton Emerging markets pioneer Mark Mobius will be stepping down as executive chairman of the Templeton Emerging Markets Group (TEMG) and formally retire from Franklin Templeton on 31 January. He will also be relinquishing his post as portfolio manager

  5. Comment - Seeding arrangements: Structure, approach, and the current market[more]

    From international law firm K&L Gates: Private fund growth has exploded over the last several years. While some areas are hotter than others, overall the industry has seen substantial growth. Existing managers have been able to launch larger funds and new managers have been able to successfully ente